title: [Insulin sensitizing drugs].
abstract: Currently, insulin sensitizing drugs in the form of metformin as the basic drug are part of the treatment of practically any type II diabetic patient. At the beginning of the therapy, metformin is used; later, insulin sensitizers (PPAR-gamma stimulators) such as rosiglitazone and pioglitazone are often applied. Nowadays, extensive research into new pharmaceuticals is being conducted in the group of insulin sensitizers. So-called double sensitizers, panPPAR sensitizers or PPAR-delta sensitizers, are being developed. The most promising group is of the PPAR-gamma selective modulators.
authors.affiliation: Diabetologické centrum, Kliniky gerontologické a metabolické Lékarské fakulty UK a FN Hradec Králové. smahelov@lfhk.cuni.cz
authors.forename: A
authors.initials: A
authors.lastname: Smahelová
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000378:metabolism*; D047495:PPAR gamma / Q000819:agonists; D000077205:Pioglitazone; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000627:therapeutic use
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin; D047495:PPAR gamma; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D000077205:Pioglitazone